Parasitology Research

, Volume 111, Issue 5, pp 1871–1877

Susceptibility or resistance of praziquantel in human schistosomiasis: a review

Review

Abstract

Since praziquantel was developed in 1970s, it has replaced other antischistosomal drugs to become the only drug of choice for treatment of human schistosomiases, due to high efficacy, excellent tolerability, few and transient side effects, simple administration, and competitive cost. Praziquantel-based chemotherapy has been involved in the global control strategy of the disease and led to the control strategy shifting from disease control to morbidity control, which has greatly reduced the prevalence and intensity of infections. Given that the drug has been widely used for morbidity control in endemic areas for more than three decades, the emergence of resistance of Schistosoma to praziquantel under drug selection pressure has been paid much attention. It is possible to induce resistance of Schistosoma mansoni and Schistosoma japonicum to praziquantel in mice under laboratorial conditions, and a reduced susceptibility to praziquantel in the field isolates of S. mansoni has been found in many foci. In addition, there are several schistosomiasis cases caused by Schistosoma haematobium infections in which repeated standard treatment fails to clear the infection. However, in the absence of exact mechanisms of action of praziquantel, the mechanisms of drug resistance in schistosomes remain unclear. The present review mainly demonstrates the evidence of drug resistance in the laboratory and field and the mechanism of praziquantel resistance and proposes some strategies for control of praziquantel resistance in schistosomes.

References

  1. Abdel-Hafeez EH, Ahmad AK, Abdulla AM, Aabdel-Wahab S, Mosalem FA (2012) Therapeutic effect of alpha lipoic acid combined with praziquantel on liver fibrosis induced by Schistosoma mansoni challenged mice. Parasitol Res 111:577–586PubMedCrossRefGoogle Scholar
  2. Alonso D, Muñoz J, Gascón J, Valls ME, Corachan M (2006) Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 74:342–344PubMedGoogle Scholar
  3. Blackhall WJ, Liu HY, Xu M, Prichard RK, Beech RN (1998) Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Mol Biochem Parasitol 95:193–201PubMedCrossRefGoogle Scholar
  4. Blackhall WJ, Prichard RK, Beech RN (2008) P-glycoprotein selection in strains of Haemonchus contortus resistant to benzimidazoles. Vet Parasitol 152:101–107PubMedCrossRefGoogle Scholar
  5. Bonesso-Sabadini PI, de Souza Dias LC (2002) Altered response of strain of Schistosoma mansoni to oxamniquine and praziquantel. Mem Inst Oswaldo Cruz 97:381–385PubMedCrossRefGoogle Scholar
  6. Bosch IB, Wang ZX, Tao LF, Shoemaker CB (1994) Two Schistosoma mansoni cDNAs encoding ATP-binding cassette (ABC) family proteins. Mol Biochem Parasitol 65:351–356PubMedCrossRefGoogle Scholar
  7. Botros S, El-Lakkany N, SH Se-D, Sabra AN, Ibrahim M (2011) Comparative efficacy and bioavailability of different praziquantel brands. Exp Parasitol 127:515–521PubMedCrossRefGoogle Scholar
  8. Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433–439PubMedCrossRefGoogle Scholar
  9. Campos R, Moreira AA, Sette H Jr, Chamone DA, Da Silva LC (1976) Hycanthone resistance in a human strain of Schistosoma mansoni. Trans R Soc Trop Med Hyg 70:261–262PubMedCrossRefGoogle Scholar
  10. Chen MG (2005) Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience. Acta Trop 96:168–176PubMedCrossRefGoogle Scholar
  11. Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13:659–663PubMedCrossRefGoogle Scholar
  12. Coles GC (1989) Mass treatment of schistosomiasis. Parasitol Today 5:214PubMedCrossRefGoogle Scholar
  13. Coles GC, Bruce JI (1987) In vitro selection of drug resistant Schistosoma mansoni. Int J Parasitol 17:767–771PubMedCrossRefGoogle Scholar
  14. Coles GC, Kinoti GK (1997) Defining resistance in Schistosoma. Parasitol Today 13:57–158CrossRefGoogle Scholar
  15. Couto FF, Coelho PM, Araújo N, Kusel JR, Katz N, Jannotti-Passos LK, Mattos AC (2011) Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz 106:153–157PubMedGoogle Scholar
  16. Danso-Appiah A, De Vlas SJ (2002) Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18:125–129PubMedCrossRefGoogle Scholar
  17. Dias LC, Olivier CE (1986) Failure at inducing resistance to schistosomicidal drugs in a Brazilian human strain of Schistosoma mansoni. Rev Inst Med Trop Sao Paulo 28:352–357PubMedCrossRefGoogle Scholar
  18. Doenhoff MJ, Pica-Mattoccia L (2006) Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther 4:199–210PubMedCrossRefGoogle Scholar
  19. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96:465–469PubMedCrossRefGoogle Scholar
  20. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659–667PubMedCrossRefGoogle Scholar
  21. Drescher KM, Rogers EJ, Bruce JI, Katz N, Dias LC, Coles GC (1993) Response of drug resistant isolates of Schistosoma mansoni to antischistosomal agents. Mem Inst Oswaldo Cruz 88:89–95PubMedCrossRefGoogle Scholar
  22. Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51:83–88PubMedGoogle Scholar
  23. Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1994) Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61–62Google Scholar
  24. Fenwick A (2012) The global burden of neglected tropical diseases. Public Health 126:233–236PubMedCrossRefGoogle Scholar
  25. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19:509–515PubMedCrossRefGoogle Scholar
  26. French MD, Churcher TS, Gambhir M, Fenwick A, Webster JP, Kabatereine NB, Basáñez MG (2010) Observed reductions in Schistosoma mansoni transmission from large-scale administration of praziquantel in Uganda: a mathematical modelling study. PLoS Negl Trop Dis 4:e897PubMedCrossRefGoogle Scholar
  27. Gatti L, Cossa G, Beretta GL, Zaffaroni N, Perego P (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 18:4237–4249PubMedCrossRefGoogle Scholar
  28. Geerts S, Coles GC, Gryseels B (1997) Anthelmintic resistance in human helminths: learning from the problems with worm control in livestock. Parasitol Today 13:149–151PubMedCrossRefGoogle Scholar
  29. Geisler M, Murphy AS (2006) The ABC of auxin transport: the role of p-glycoproteins in plant development. FEBS Lett 580:1094–1102PubMedCrossRefGoogle Scholar
  30. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42PubMedCrossRefGoogle Scholar
  31. Gönnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Parasitol Res 52:129–150Google Scholar
  32. Greenberg RM (2005) Are Ca2+ channels targets of praziquantel action? Int J Parasitol 35:1–9PubMedCrossRefGoogle Scholar
  33. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guissé F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuenté LA, Engels D, Polman K (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6:864–873PubMedCrossRefGoogle Scholar
  34. Harder A (2002) Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol Res 88:395–397PubMedGoogle Scholar
  35. Herwaldt BL, Tao LF, van Pelt W, Tsang VC, Bruce JI (1995) Persistence of Schistosoma haematobium infection despite multiple courses of therapy with praziquantel. Clin Infect Dis 20:309–315PubMedCrossRefGoogle Scholar
  36. Hong QB, Yang K, Huang YX, Sun LP, Yang GJ, Gao Y, Gao Y, Zhang LH, Zhou M, Steinmann P, Liang YS (2011) Effectiveness of a comprehensive schistosomiasis japonica control program in Jiangsu province, China, from 2005 to 2008. Acta Trop 120:S151–S157PubMedCrossRefGoogle Scholar
  37. Hotez PJ, Fenwick A (2009) Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 3:e485PubMedCrossRefGoogle Scholar
  38. Hotez PJ, Savioli L, Fenwick A (2012) Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis 6:e1475PubMedCrossRefGoogle Scholar
  39. Huang YX, Xu YL, Yu CX, Li HJ, Yin XR, Wang TS, Wang W, Liang YS (2011) Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice. Parasitol Res 109:1453–1459PubMedCrossRefGoogle Scholar
  40. Ismail MM, Taha SA, Farghaly AM, el-Azony AS (1994) Laboratory induced resistance to praziquantel in experimental schistosomiasis. J Egypt Soc Parasitol 24:685–695PubMedGoogle Scholar
  41. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55:214–218PubMedGoogle Scholar
  42. Jansma WB, Rogers SH, Liu CL, Bueding E (1977) Experimentally produced resistance of Schistosoma mansoni to hycanthone. Am J Trop Med Hyg 26:926–936PubMedGoogle Scholar
  43. Jeziorski MC, Greenberg RM (2006) Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 36:625–632PubMedCrossRefGoogle Scholar
  44. Kasinathan RS, Morgan WM, Greenberg RM (2010a) Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 173:25–31PubMedCrossRefGoogle Scholar
  45. Kasinathan RS, Goronga T, Messerli SM, Webb TR, Greenberg RM (2010b) Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J 24:128–135PubMedCrossRefGoogle Scholar
  46. Katz N, Dias EP, Araújo N, Souza CP (1973) Estudo de uma cepa humana de Schistosoma mansoni resistente a agentes esquistossomicidas. Rev Soc Bras Med Trop 7:382–387Google Scholar
  47. Kohn AB, Roberts-Misterly JM, Anderson PA, Khan N, Greenberg RM (2003) Specific sites in the beta interaction domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology 127:349–356PubMedCrossRefGoogle Scholar
  48. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, Donnelly CA, Fenwick A, Webster JP (2007) Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 196:659–669PubMedCrossRefGoogle Scholar
  49. Lawn SD, Lucas SB, Chiodini PL (2003) Schistosoma mansoni infection: failure of standard treatment with praziquantel in a returned traveller. Trans R Soc Trop Med Hyg 97:100–101PubMedCrossRefGoogle Scholar
  50. Leslie J, Garba A, Oliva EB, Barkire A, Tinni AA, Djibo A, Mounkaila I, Fenwick A (2011) Schistosomiasis and soil-transmitted helminth control in Niger: cost effectiveness of school based and community distributed mass drug administration. PLoS Negl Trop Dis 5:e1326PubMedCrossRefGoogle Scholar
  51. Lespine A, Alvinerie M, Vercruysse J, Prichard RK, Geldhof P (2008) ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol 24:293–298PubMedCrossRefGoogle Scholar
  52. Lewis VG, Ween MP, McDevitt CA (2012) The role of ATP-binding cassette transporters in bacterial pathogenicity. Protoplasma, in pressGoogle Scholar
  53. Li HJ, Liang YS, Dai JR, Wang W, Gu GL, Li YZ, Xing YT, Tao YH, Qian K, Jia Y, Yang ZK, Wei JY (2011) Studies on resistance of Schistosoma to praziquantel XIV experimental comparison of susceptibility to praziquantel between praziquantel-resistant isolates and praziquantel-susceptible isolates of Schistosoma japonicum in stages of adult worms, miracidia and cercariae. Chin J Schisto Control 23:611–619Google Scholar
  54. Liang YS, Dai JR, Ning A, Yu DB, Xu XJ, Zhu YC, Coles GC (2001a) Susceptibility of Schistosoma japonicum to praziquantel in China. Trop Med Int Health 6:707–714PubMedCrossRefGoogle Scholar
  55. Liang YS, Coles GC, Dai JR, Zhu YC, Doenhoff MJ (2001b) Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni. Ann Trop Med Parasitol 95:715–723PubMedCrossRefGoogle Scholar
  56. Liang YS, Wang W, Dai JR, Li HJ, Tao YH, Zhang JF, Li W, Zhu YC, Coles GC, Doenhoff MJ (2010) Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni. J Helminthol 84:202–207PubMedCrossRefGoogle Scholar
  57. Liang YJ, Luo J, Yuan Q, Zheng D, Liu YP, Shi L, Zhou Y, Chen AL, Ren YY, Sun KY, Sun Y, Wang Y, Zhang ZS (2011a) New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma japonicum. PLoS One 6:e20247PubMedCrossRefGoogle Scholar
  58. Liang YS, Li HJ, Dai JR, Wang W, Qu GL, Tao YH, Xing YT, Li YZ, Qian K, Wei JY (2011b) Studies on resistance of Schistosoma to praziquantel XIII resistance of Schistosoma japonicum to praziquantel is experimentally induced in laboratory. Chin J Schisto Control 23:605–610Google Scholar
  59. Martin PJ, Anderson N, Jarrett RG, Brown TH, Ford GE (1982) Effects of a preventive and suppressive control scheme on the development of thiabendazole-resistance in Ostertagia spp. Aust Vet J 58:85–190CrossRefGoogle Scholar
  60. Martin PJ, Anderson N, Lwin T, Nelson G, Morgan TE (1984) The association between frequency of thiabendazole treatment and the development of resistance in field isolates of Ostertagia spp. of sheep. Int J Parasitol 14:177–181PubMedCrossRefGoogle Scholar
  61. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504PubMedCrossRefGoogle Scholar
  62. Messerli SM, Kasinathan RS, Morgan W, Spranger S, Greenberg RM (2009) Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol 167:54–59PubMedCrossRefGoogle Scholar
  63. N'Goran EK, Gnaka HN, Tanner M, Utzinger J (2003) Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire. Ann Trop Med Parasitol 97:37–51PubMedCrossRefGoogle Scholar
  64. Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A (1998) Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92:90–93PubMedCrossRefGoogle Scholar
  65. Renganathan E, Cioli D (1998) An international initiative on praziquantel use. Parasitol Today 14:390–391PubMedCrossRefGoogle Scholar
  66. Ribeiro-dos-Santos G, Verjovski-Almeida S, Leite LC (2006) Schistosomiasis—a century searching for chemotherapeutic drugs. Parasitol Res 99:505–521PubMedCrossRefGoogle Scholar
  67. Rodrigues AS, Dinis J, Gromicho M, Martins C, Laires A, Rueff J (2012) Genomics and cancer drug resistance. Curr Pharm Biotechnol 13:651–673PubMedCrossRefGoogle Scholar
  68. Seto EY, Wong BK, Lu D, Zhong B (2011) Human schistosomiasis resistance to praziquantel in China: should we be worried? Am J Trop Med Hyg 85:74–82PubMedCrossRefGoogle Scholar
  69. Seubert J, Pohlke R, Loebich F (1977) Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia 33:1036–1037PubMedCrossRefGoogle Scholar
  70. Silva IM, Thiengo R, Conceição MJ, Rey L, Lenzi HL, Pereira Filho E, Ribeiro PC (2005) Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz 100:445–449PubMedGoogle Scholar
  71. Silva IM, Pereira Filho E, Thiengo R, Ribeiro PC, Conceição MJ, Panasco M, Lenzi HL (2008) Schistosomiasis haematobia: histopathological course determined by cystoscopy in a patient in whom praziquantel treatment failed. Rev Inst Med Trop Sao Paulo 50:343–346PubMedCrossRefGoogle Scholar
  72. Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 176:304–307PubMedCrossRefGoogle Scholar
  73. Sun LP, Wang W, Liang YS, Tian ZX, Hong QB, Yang K, Yang GJ, Dai JR, Gao Y (2011) Effect of an integrated control strategy for schistosomiasis japonica in the lower reaches of the Yangtze River, China: an evaluation from 2005 to 2008. Parasit Vectors 4:243PubMedCrossRefGoogle Scholar
  74. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M (2000) Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 5:771–778PubMedCrossRefGoogle Scholar
  75. Valle C, Troiani AR, Festucci A, Pica-Mattoccia L, Liberti P, Wolstenholme A, Francklow K, Doenhoff MJ, Cioli D (2003) Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol Biochem Parasitol 130:111–115PubMedCrossRefGoogle Scholar
  76. Wang W, Liang YS (2007) Progress on research of resistance of schistosome to praziquantel. Int J Med Parasit Dis 34:291–296,300Google Scholar
  77. Wang LD, Chen HG, Guo JG, Zeng XJ, Hong XL, Xiong JJ, Wu XH, Wang XH, Wang LY, Xia G, Hao Y, Chin DP, Zhou XN (2009a) A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 360:121–128PubMedCrossRefGoogle Scholar
  78. Wang LD, Guo JG, Wu XH, Chen HG, Wang TP, Zhu SP, Zhang ZH, Steinmann P, Yang GJ, Wang SP, Wu ZD, Wang LY, Hao Y, Bergquist R, Utzinger J, Zhou XN (2009b) China’s new strategy to block Schistosoma japonicum transmission: experiences and impact beyond schistosomiasis. Trop Med Int Health 14:1475–1483PubMedCrossRefGoogle Scholar
  79. Wang W, Dai JR, Li HJ, Shen XH, Liang YS (2010) Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Parasitology 137:1905–1912PubMedCrossRefGoogle Scholar
  80. Wang W, Dai JR, Li HJ, Shen XH, Liang YS (2012) The sensitivity of Schistosoma japonicum to praziquantel: a field evluation in areas with low endemicity of China. Am J Trop Med Hyg 86:834–836PubMedCrossRefGoogle Scholar
  81. Wawrzycka D (2011) The ABC transporters of Saccharomyces cerevisiae. Postepy Biochem 57:324–332PubMedGoogle Scholar
  82. WHO (1993) The control of schistosomiasis: Second Report of WHO Expert Committee. Geneva: World Health Organization, Technical Report Series, No. 830, GenevaGoogle Scholar
  83. WHO (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Technical Report Series 912, GenevaGoogle Scholar
  84. Wu W, Wang W, Huang YX (2011) New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 109:1501–1507PubMedCrossRefGoogle Scholar
  85. Xianyi C, Liying W, Jiming C, Xiaonong Z, Jiang Z, Jiagang G, Xiaohua W, Engels D, Minggang C (2005) Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992–2001). Bull World Health Organ 83:43–48PubMedGoogle Scholar
  86. Xiao SH, Mei JY, Jiao PY (2009) The in vitro effect of mefloquine and praziquantel against juvenile and adult Schistosoma japonicum. Parasitol Res 106:237–246PubMedCrossRefGoogle Scholar
  87. Xiao SH, Keiser J, Chen MG, Tanner M, Utzinger J (2010) Research and development of antischistosomal drugs in the People’s Republic of China a 60-year review. Adv Parasitol 73:231–295PubMedCrossRefGoogle Scholar
  88. Xiao SH, Mei JY, Jiao PY (2011) Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum. Parasitol Res 108:399–406PubMedCrossRefGoogle Scholar
  89. Xiao SH, Xue J, Zhang HB (2012) Further studies on mefloquine and praziquantel alone or interaction of both drugs against Schistosoma japonicum in vitro. Parasitol Res 110:1239–1248PubMedCrossRefGoogle Scholar
  90. Yu DB, Li Y, Sleigh AC, Yu XL, Li YS, Wei WY, Liang YS, McManus DP (2001) Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China. Trans R Soc Trop Med Hyg 95:537–541PubMedCrossRefGoogle Scholar
  91. Yue WJ, Yu SH, Xu XJ (1990) Failure to induce resistance of Schistosoma japonicum to praziquantel. Southeast Asian J Trop Med Public Health 21:85–89PubMedGoogle Scholar
  92. Zhai ZL, Xiao SH, Chen MG, Zheng J (1999) A worrying problem: is there resistance of schistosome to praziquantel? Chin J Schisto Control 11:121–124Google Scholar
  93. Zhang Y, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E, Stothard JR, Webster JP, Fenwick A (2007) Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med 5:27PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Jiangsu Institute of Parasitic DiseasesWuxi CityPeople’s Republic of China
  2. 2.Key Laboratory on Technology for Parasitic Disease Prevention and ControlMinistry of HealthWuxi CityPeople’s Republic of China
  3. 3.Wuxi Institute for Drug ControlWuxi CityPeople’s Republic of China

Personalised recommendations